Form 4: EcoR1 Capital Increases Stake in Zymeworks Inc. Through Open Market Purchases

EcoR1 Capital, a significant shareholder in Zymeworks Inc., has increased its holdings through a series of open market purchases of common stock.

Summary

• EcoR1 Capital, LLC, along with Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P., have reported changes in their beneficial ownership of Zymeworks Inc. common stock.
• Between March 31, 2025, and April 2, 2025, EcoR1 Capital Fund Qualified, L.P. purchased a total of 128,709 shares of Zymeworks Inc. common stock.
• The purchases were made in multiple transactions at prices ranging from $11.6044 to $11.848 per share.
• Following these transactions, EcoR1 Capital Fund Qualified, L.P. directly holds 16,294,087 shares of Zymeworks Inc. common stock.
• EcoR1 Capital, as the investment advisor to the Funds, and Mr. Nodelman, as the control person of EcoR1, may be deemed to indirectly beneficially own these shares.
• Both EcoR1 Capital and Mr. Nodelman disclaim beneficial ownership of the securities except to the extent of their respective pecuniary interests therein.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The increased investment suggests confidence, but it's a routine transaction.

Positives

• EcoR1 Capital's increased investment in Zymeworks Inc. could be interpreted as a sign of confidence in the company's future prospects.

Risks

• The document does not explicitly state any risks.
• However, it is important to note that increased ownership by a single entity could potentially lead to greater influence over the company's decisions.

Industry Context

This announcement reflects ongoing investment activity in the biotechnology sector, where firms like Zymeworks are developing novel therapies. Monitoring ownership changes can provide insights into investor sentiment and potential strategic shifts.

Comparison to Industry Standards

• Comparing EcoR1's investment in Zymeworks to similar investments by venture capital and private equity firms in comparable biotech companies could provide a benchmark for assessing the significance of this transaction.
• For example, consider the investment patterns of firms like Orbimed, RA Capital Management, or Flagship Pioneering in companies with similar market capitalization and therapeutic focus.
• Analyzing the average ownership stake held by institutional investors in the biotech industry can also provide context.

Stakeholder Impact

• The increased stake by EcoR1 Capital could reassure shareholders about the company's prospects.
• It may also influence the company's strategic direction, given EcoR1's significant ownership.

Key Dates

Keywords

Zymeworks, EcoR1 Capital, Beneficial Ownership, Common Stock, Share Purchases, Nodelman, Investment